drugs never leave patent. they can't enter the market to compete. another is rigid fda regulations costly and time consuming to put new drug. use legal challenges to deter competition. and of course greed plays a role, too. that's a word we don't use very often but still real. one of the dead sins for good reason. whatever the reasons for the spike in prices in insulin, it's a huge problem. and you would think it's something that congress and the administration would consider taking action on. there are some things they could do. maybe they should streamline an fda approval process or adjust patent law. maybe they should subsidize the creation of a generic insulin brand. after all we spend billions subsidizing solar panels and electric cars only rich people can afford. once you give lecture about the market remind you we do that we are not scientists or economists we can say this is a real problem that congress appears to be ignoring. in october, the president pitched a plan to lower drug